AVS Bio acquires UK bioreagent supplier Biorbyt to expand biomaterials catalog

AVS Bio expands into life science research reagents

AVS Bio, a Norwich, Connecticut-based provider of critical inputs and services for the bioprocessing and biologics industries, announced it has acquired Biorbyt Ltd., a global supplier of bio-reagents, antibodies, proteins, and other biomaterials used in life science research. The deal is intended to significantly expand AVS Bio's catalog of research products and add global distribution capabilities through Biorbyt's ecommerce platform, advancing AVS Bio's positioning as a diversified biomaterials provider serving pharmaceutical, biotech, and academic customers.

Biorbyt's catalog and global reach

Founded in 2011 and headquartered in Cambridge, UK, Biorbyt offers a catalog of more than 1 million SKUs spanning primary and secondary antibodies, recombinant and native proteins, ELISA kits, small molecules, and molecular biology reagents. The company also provides custom antibody development, peptide synthesis, and protein expression services, and distributes its portfolio through a digital commerce channel to pharmaceutical, biotech, and academic researchers worldwide. Following the acquisition, Biorbyt will continue to operate under its existing leadership as part of the AVS Bio platform, with access to a broader set of complementary reagents and biomaterials offered through a single integrated channel.

Arlington Capital Partners' platform strategy

AVS Bio is a portfolio company of Arlington Capital Partners, a Washington, D.C.-area private investment firm that focuses on government-regulated industries. Malcolm Little, a Partner at Arlington Capital Partners, framed the deal as a continuation of an effort to build AVS Bio into a scaled life sciences platform with capabilities spanning the research and development lifecycle, adding digital commerce capabilities and Biorbyt's scientific and commercial leadership to AVS Bio's existing footprint. The acquisition was described in the announcement as an add-on transaction for the AVS Bio platform.

Evidence limits and undisclosed terms

The announcement did not disclose the financial terms of the transaction, the size of the combined catalog or revenue base, or any timeline for integrating Biorbyt's ecommerce operations into AVS Bio's broader business. Independent coverage of the deal's valuation, financing structure, or regulatory review status was not present in the available source set.